All patients | Baseline CTC < 5 | Baseline CTC ≥5 | P value | Baseline clusters absent | Baseline clusters ≥ 1 | P value | |
---|---|---|---|---|---|---|---|
(n = 156) | (n = 73) | (n = 79) | (n = 122) | (n = 30) | |||
Age MBC, median (range) | 65 (40–90) | 65 (40–-84) | 65 (41–90) | 0.71a | 67 (40–90) | 60 (42–72) | 0.002a |
Baseline ECOG | |||||||
0 | 91 | 48 (53) | 43 (47) | 0.07b | 76 (84) | 15 (16) | 0.32b |
1 | 37 | 17 (46) | 20 (54) | 29 (78) | 8 (22) | ||
2 | 22 | 6 (30) | 14 (70) | 15 (75) | 5 (25) | ||
Unknown | 6 | ||||||
PT NHG | |||||||
I | 13 | 9 (69) | 4 (31) | 0.58b | 12 (92) | 1 (8) | 0.85b |
II | 65 | 26 (41) | 38 (59) | 47 (73) | 17 (27) | ||
III | 46 | 22 (49) | 23 (51) | 38 (84) | 7 (16) | ||
Unknown | 32 | ||||||
PT tumor size | |||||||
T1 | 57 | 30 (55) | 25 (45) | 0.16b | 49 (89) | 6 (11) | 0.07b |
T2 | 51 | 25 (49) | 26 (51) | 39 (76) | 12 (24) | ||
T3 | 20 | 8 (40) | 12 (60) | 15 (75) | 5 (25) | ||
T4 | 19 | 7 (39) | 11 (61) | 13 (72) | 5 (28) | ||
Unknown | 9 | ||||||
PT node status | |||||||
Negative | 44 | 27 (61) | 17 (39) | 0.04c | 39 (89) | 5 (11) | 0.10c |
Positive | 92 | 38 (42) | 52 (58) | 69 (77) | 21 (23) | ||
Unknown | 20 | ||||||
Breast cancer subtyped | |||||||
ER+ HER2- | 105 | 46 (44) | 58 (56) | 0.52c | 86 (83) | 18 (17) | 0.34c |
HER2+ | 20 | 11 (58) | 8 (42) | 14 (74) | 5 (26) | ||
ER- HER2- | 26 | 12 (50) | 12 (50) | 17 (71) | 7 (29) | ||
Unknown | 5 | ||||||
Metastasis-free interval (years) | |||||||
0 | 31 | 14 (47) | 16 (53) | 0.57b | 24 (80) | 6 (20) | 0.97b |
> 0-3 | 28 | 11 (41) | 16 (59) | 22 (81) | 5 (19) | ||
> 3 | 97 | 48 (51) | 47 (49) | 76 (80) | 19 (20) | ||
Metastatic sites, number | |||||||
< 3 | 109 | 58 (54) | 49 (46) | 0.02c | 88 (82) | 19 (18) | 0.34c |
≥ 3 | 47 | 15 (33) | 30 (67) | 34 (76) | 11 (24) | ||
Site of metastasis | |||||||
Non-visceral | 65 | 29 (45) | 35 (55) | 0.57c | 47 (73) | 17 (27) | 0.07c |
Viscerale | 91 | 44 (50) | 44 (50) | 75 (85) | 13 (15) | ||
1st line treatment for MBCf | |||||||
Endocrine | 58 | 31 (53) | 27 (47) | 0.28c | 56 (97) | 2 (3) | < 0.001c |
Chemotherapy | 71 | 29 (42) | 40 (58) | 48 (70) | 21 (30) | ||
HER2-targeted | 15 | 9 (60) | 6 (40) | 11 (73) | 4 (27) | ||
One or more clusters of ≥ 2 CTCs at baselineg | |||||||
No | 122 | 73 (60) | 49 (40) | < 0.001c | |||
Yes | 30 | 0 | 30 (100) |